The mRNA-LNP Decisions That Shape In-Vivo CAR-T Translation

In vivo CAR-T therapies offer a potential alternative to conventional autologous ex vivo approaches by delivering mRNA directly to immune cells using lipid nanoparticles (LNPs). Early formulation decisions influence cellular delivery, endosomal escape, CAR expression, biodistribution, stability, and manufacturing scalability. Preclinical mRNA-LNP cancer vaccine studies demonstrate efficient delivery, functional protein expression, antitumor activity, and tolerability following repeated administration in mouse models. Although cancer vaccines and in vivo CAR-T therapies differ in their mechanisms of action, these findings provide useful precedents for evaluating payload complexity, repeat dosing, and formulation performance.

Stabilizing lipids are another important formulation variable. Polyethylene glycol (PEG)-lipids support colloidal stability and can reduce systemic clearance, but anti-PEG antibodies, hypersensitivity concerns, and limitations in formulation flexibility have prompted investigation of alternative chemistries. Proof-of-concept studies of non-PEG stabilizers have demonstrated maintenance of key critical quality attributes alongside improved in vivo and ex vivo efficacy. Further research has shown potential for liver de-targeting and spleen tropism, which may help developers refine tissue distribution.

For in vivo CAR-T programs, formulation development must establish reproducible relationships between administered dose, targeted cellular delivery, and functional CAR expression. Optimizing lipid composition, particle characteristics, encapsulation efficiency, and stability can help control therapeutic performance while supporting scalable manufacturing, appropriate quality controls, and reduced downstream development risk.